Previous 10 | Next 10 |
Few stocks have performed better than Vaxart (NASDAQ: VXRT) of late. Year to date, shares of this company are up by more than 3,400%. And despite these massive gains, Vaxart's market cap is still just $1.34 billion, a reasonable level for a clinical-stage biotech. Vaxart's efforts to develo...
Biotech Pulse Biotechs continue to be one of the leading healthcare groups and along with diagnostics represent two of the best segments of healthcare. The first half saw biotechs recover quicker from the March selloff than most of the market, and reach a milestone that took 5 years to achie...
Some of the biggest winners of 2020 so far have been small biotechs that are developing COVID-19 vaccine candidates. Shares of Inovio Pharmaceuticals (NASDAQ: INO) , for example, have soared well over 500% year to date. Vaxart (NASDAQ: VXRT) stock is up more than 3,000%. Some invest...
BERWYN, Pa. , July 27, 2020 /PRNewswire/ -- RM LAW, P.C. announces an investigation on behalf of Vaxart, Inc. ("Vaxart" or the "Company") (NASDAQ: VXRT) investors concerning the Company and its officers' possible violations of federal securities laws. If you purc...
Gainers: Wilhelmina International (NASDAQ: WHLM ) +192% . More news on: Wilhelmina International, Inc., Socket Mobile, Inc., MediciNova, Inc., Stocks on the move, , Read more ...
WISeKey International WKEY -20% . More news on: Vaxart, Inc., PolarityTE, Inc., Sunworks, Inc., Stocks on the move, , Read more ...
Many companies' business prospects have been hurt as a result of the COVID-19 pandemic. Lockdowns and general public wariness about being infected by the novel coronavirus have taken a toll. But there are also some companies that have seen their business prospects soar due to the viral outbreak ...
Robinhood investors are known for their capricious and sometimes idiosyncratic trading activity, but it would be folly to discount their growing effect on the price of small-cap stocks. Especially for nascent or clinical-stage biotech companies without any products approved for sale, a spurt of ...
Rather than wowing speculators with promises of a scientific breakthrough, Emergent BioSolutions ' (NYSE: EBS) coronavirus strategy positions the company as the go-to resource for vaccine manufacturing support. Aside from its ever-increasing number of contract manufacturing agreements with ma...
Investors sold off shares of several coronavirus vaccine-related stocks on Friday as lawmakers ramp up pressure on drugmakers. By the close of trading, shares of Vaxart (NASDAQ: VXRT) , Inovio Pharmaceuticals (NASDAQ: INO) , BioNTech (NASDAQ: BNTX) , and Moderna (NASDAQ: MRNA) we...
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World Vaccine Congress Washington 2024 in Washington, D.C. on Wednesday, April 3, 2024. The Company has appea...
SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) (the "Company" or "Vaxart") today announced that the ...
SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that the Compensation Committee of the Board of Directors approved certain equity awards to the Company’s new President and Ch...